Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Roivant Flips a Skin Drug to Organon
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.
Organon to acquire Dermavant in $1.2B deal
The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.
Skin deep: Organon buys Dermavant for $1.2B
Roivant Sciences Ltd. has sold another company, this time offering up Dermavant Sciences Ltd. to Organon & Co. for $1.2 billion. The deal brings Organon into a crowded market for plaque psoriasis treatments.
Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 Billion
Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make an up-front payment of $175 million, along with up to $1.025 billion in milestone payments.
Organon To Buy Dermavant For Around $1.2 Bln
Roivant Sciences Ltd. (ROIV), developer and commercializer of immuno-dermatology therapeutics, announced on Wednesday that it has
Organon to buy skin therapy developer Dermavant for up to $1.2 billion
(Reuters) -Healthcare company Organon said on Wednesday it has agreed to acquire skin therapy developer Dermavant, a unit of Roivant, for up to $1.2 billion. Organon will make an upfront payment of $175 million,
Organon to Buy Roivant's Dermatology Unit For Up to $1.2 Billion
Organon (OGN) on Wednesday agreed to acquire Roivant Sciences' (ROIV) immuno-dermatology subsidiary, Dermavant, in a deal worth up to $1.2 billion. The healthcare company will pay $175 million upfront and up to $950 million for the achievement of certain commercial milestones.
GlobalData on MSN
20h
Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary
As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...
Pharmabiz
5h
Organon to buy Dermavant Sciences including its innovative dermatologic therapy, Vtama cream 1% to treat plaque psoriasis
Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...
16h
Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...
1d
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including ...
FiercePharma
2d
Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama
Organon will also furnish Dermavant with a $75 million milestone payment contingent upon
Vtama
’s approval in atopic ...
1d
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...
pharmaphorum
1d
Organon makes dermatology play with $1.2bn Dermavant buyout
Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Dermavant
Organon
Roivant
Food and Drug Administration
Feedback